Scholarlink

Background <p>Cyclic guanosine monophosphate (cGMP)-mediated mechanisms plays a role in migraine pathophysiology. Sildenafil, a phosphodiesterase type 5 inhibitor, increases intracellular cGMP and can reliably induce migraine attacks in women. However, its migraine-inducing potential in men remains largely unknown.</p> Methods <p>In this randomized, double-blind, placebo-controlled crossover trial, 12 men with migraine without aura received sildenafil (100&#xa0;mg) and placebo in separate sessions ≥ 7 days apart. An open-label parallel cohort of 15 women with migraine received sildenafil (100&#xa0;mg) under similar experimental conditions. The primary endpoints were (i) the incidence of migraine-like attacks after sildenafil compared with placebo in men, and (ii) the incidence of migraine-like attacks after sildenafil in men and women.</p> Results <p>In men, sildenafil induced headache more frequently than placebo (83% vs. 25%, <i>p</i> = 0.033), whereas the incidence of migraine-like attacks did not differ between sildenafil and placebo (25% vs. 17%, <i>p</i> = 0.500). In women, sildenafil induced headache in all participants and migraine-like attacks in 67%, a significantly higher proportion than in men (67% vs. 25%, <i>p</i> = 0.038). Adverse events were more frequent after sildenafil than placebo, most commonly flushing and nasal congestion.</p> Conclusions <p>Sildenafil provoked headache but not migraine in men with migraine without aura, whereas women showed a markedly greater susceptibility to migraine induction. These findings suggest that cGMP-mediated mechanisms contribute less prominently to migraine generation in men.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sildenafil provokes headache but not migraine in men with migraine without aura: a randomized, placebo-controlled crossover trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月10日

查看全文
  • Anas Mohammad,
  • Ditte Bork Iversen,
  • Nete Lundager Klokker Rausgaard,
  • Christina Kruuse,
  • Dagmar Beier,
  • Tore Bjerregaard Stage,
  • Lanfranco Pellesi

摘要

Background

Cyclic guanosine monophosphate (cGMP)-mediated mechanisms plays a role in migraine pathophysiology. Sildenafil, a phosphodiesterase type 5 inhibitor, increases intracellular cGMP and can reliably induce migraine attacks in women. However, its migraine-inducing potential in men remains largely unknown.

Methods

In this randomized, double-blind, placebo-controlled crossover trial, 12 men with migraine without aura received sildenafil (100 mg) and placebo in separate sessions ≥ 7 days apart. An open-label parallel cohort of 15 women with migraine received sildenafil (100 mg) under similar experimental conditions. The primary endpoints were (i) the incidence of migraine-like attacks after sildenafil compared with placebo in men, and (ii) the incidence of migraine-like attacks after sildenafil in men and women.

Results

In men, sildenafil induced headache more frequently than placebo (83% vs. 25%, p = 0.033), whereas the incidence of migraine-like attacks did not differ between sildenafil and placebo (25% vs. 17%, p = 0.500). In women, sildenafil induced headache in all participants and migraine-like attacks in 67%, a significantly higher proportion than in men (67% vs. 25%, p = 0.038). Adverse events were more frequent after sildenafil than placebo, most commonly flushing and nasal congestion.

Conclusions

Sildenafil provoked headache but not migraine in men with migraine without aura, whereas women showed a markedly greater susceptibility to migraine induction. These findings suggest that cGMP-mediated mechanisms contribute less prominently to migraine generation in men.

Graphical abstract